Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparison of Delafloxacin Versus Ceftriaxone for the Treatment of Uncomplicated Gonorrhea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02015637
Recruitment Status : Terminated
First Posted : December 19, 2013
Results First Posted : April 26, 2018
Last Update Posted : June 20, 2018
Sponsor:
Information provided by (Responsible Party):
Melinta Therapeutics, Inc.

Brief Summary:
The purpose of this study is to evaluate the effects of a single oral dose of delafloxacin versus a single intramuscular injection of ceftriaxone in subjects with uncomplicated cervical, urethral, rectal, or pharyngeal gonorrhea.

Condition or disease Intervention/treatment Phase
Gonorrhea Drug: Delafloxacin Drug: Ceftriaxone Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 460 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Comparative Evaluation of the Single-dose Efficacy of Oral Delafloxacin Versus the Single-dose Efficacy of an Intramuscular Injection of Ceftriaxone in Subjects With Uncomplicated Urogenital Gonorrhea
Actual Study Start Date : January 23, 2014
Actual Primary Completion Date : November 2014
Actual Study Completion Date : December 10, 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Gonorrhea

Arm Intervention/treatment
Experimental: Delafloxacin
900mg orally (2 x 450 mg tablets) administered once
Drug: Delafloxacin
single dose

Active Comparator: ceftriaxone
Ceftriaxone 250 mg intramuscular injection administered once
Drug: Ceftriaxone
single dose




Primary Outcome Measures :
  1. Number of Subjects With Cure or Failure of Urogenital Gonorrhea at Test of Cure (TOC) in the Urogenital MITT (UMITT) Population [ Time Frame: Day 7 (± 3 days) ]
    Cure for the primary outcome measure was defined as the eradication of N. gonorrhoeae at TOC as determined by a negative culture obtained from the urogenital site, which was positive at study entry, and with no additional antibiotics with activity against N. gonorrhoeae being administered from study entry through TOC.


Secondary Outcome Measures :
  1. Number of Subjects With Cure or Failure of Urogenital Gonorrhea at Test of Cure (TOC) in the Urogenital Microbiologically Evaluable (UME) Population [ Time Frame: Day 7 (± 3 days) ]
    Cure for the seconday outcome measure was defined as the eradication of N. gonorrhoeae at TOC as determined by a negative culture obtained from the urogenital site, which was positive at study entry, and with no additional antibiotics with activity against N. gonorrhoeae being administered from study entry through TOC.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   15 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject is a male or female 15 years of age or older.
  • Subject must have had 1 or more of the following occur:

    1. gonorrhea with the nucleic acid amplification test (NAAT) or culture within the previous 14 days
    2. unprotected genital contact within 14 days with a person confirmed to be infected with gonorrhea,
    3. gram-negative present in urogenital gram strain or male subject must present with purulent urethritis or a female subject with must present with mucopurulent cervical discharge
  • Subject agrees to avoid unprotected sexual contact in order to minimize the risk of gonorrhea reinfection
  • Subject must be in good health (ie, based on medical history), as determined by the investigator.
  • In the opinion of the investigator, the subject must be able and willing to comply with protocol requirements. The subject must agree to provide reliable, verifiable contact information and agree to return for the Test-of-Cure Visit.
  • If a subject's age is 15 years to less than the legal age of consent,a written, voluntarily signed assent must be obtained from the subject and a written, voluntarily signed informed consent must be signed by the subject's parent or legal guardian before the initiation of any study related procedures, unless the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) determines that parent/legal guardian consent is not required.

Exclusion Criteria:

  • Confirmed, or suspected, complicated or systemic gonococcal infection, such as pelvic inflammatory disease, arthritis, or endocarditis.
  • Subject has taken one of the following products within 6 hours of the Entry Visit that may interfere with the absorption of a quinolone antibiotic: magnesium/aluminum antacids; sucralfate; Videx® (didanosine) chewable/buffered tablets; other highly buffered drugs; or other products containing calcium, iron, or zinc.
  • Use of systemic or intravaginal antibiotics that are potentially effective against gonorrhea 4 weeks prior to study drug administration.
  • Subjects with a current or prior history of seizures, and subjects being treated with drugs that are known to have a sizable potential of or reduce the threshold for inducing seizures (eg, bupropion, theophylline, and tricyclic and tetracyclic antidepressants).
  • Current use of systemic corticosteroid or immunosuppressive drugs.
  • Known significant immunosuppression (eg, cluster of differentiation (CD4) cell count <200/mm3 or absolute neutrophil count <500/mL).
  • Cytotoxic chemotherapy or radiation therapy during the previous 3 months.
  • Subject is co-infected with an additional sexually transmitted disease (STD) for which treatment cannot be safely deferred until after the Test-of-Cure Visit unless the treatment is not potentially effective against gonorrhea.
  • Subject has used an investigational drug or product within 30 days before study drug dosing.
  • Medical history of Type 1 hypersensitivity to antibiotics of the quinolone or cephalosporin classes.
  • Hysterectomized subjects without a cervix are ineligible.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02015637


Locations
Layout table for location information
United States, Alabama
Melinta 304 Study
Birmingham, Alabama, United States, 35294
United States, California
Melinta 304 Study Site
Chula Vista, California, United States, 90911
Melinta 304 Study Site
La Mesa, California, United States, 91942
Melinta 304 Study Site
Los Angeles, California, United States, 90069
Melinta 304 Study Site
San Francisco, California, United States, 94103
United States, Georgia
Melinta 304 Study
Atlanta, Georgia, United States, 30308
Melinta 304 Study
Decatur, Georgia, United States, 30033
United States, Indiana
Melinta 304 Study Site
Indianapolis, Indiana, United States, 46202
United States, Louisiana
Melinta 304 Study Site
New Orleans, Louisiana, United States, 70112
United States, Nebraska
Melinta 304 Study Site
Omaha, Nebraska, United States, 68114
United States, Nevada
Melinta 304 Study Site
Las Vegas, Nevada, United States, 89109
United States, New York
Melinta 304 Study Site
Bronx, New York, United States, 100461
Melinta 304 Study Site
Brooklyn, New York, United States, 11203
Melinta 304 Study
Brooklyn, New York, United States, 11203
Melinta 304 Study Site
New York, New York, United States, 10018
United States, North Carolina
Melinta 304 Study Site
Durham, North Carolina, United States, 27701
Melinta 304 Study Site
Greensboro, North Carolina, United States, 27405
United States, Ohio
Melinta 304 Study Site
Cleveland, Ohio, United States, 44108
Melinta 304 Study Site
Columbus, Ohio, United States, 43231
United States, Oregon
Melinta 304 Study Site
Portland, Oregon, United States, 97204
United States, Pennsylvania
Melinta 304 Study
Erie, Pennsylvania, United States, 16507
Melinta 304 Study Site
Philadelphia, Pennsylvania, United States, 191007
Melinta 304 Study Site
Pittsburgh, Pennsylvania, United States, 15213
United States, Texas
Melinta 304 Study Site
Houston, Texas, United States, 77011
United States, Washington
Melinta 304 Study Site
Seattle, Washington, United States, 98104
Sponsors and Collaborators
Melinta Therapeutics, Inc.
Investigators
Layout table for investigator information
Study Director: Sue Cammarata, MD Melinta Therapeutics, Inc.
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Melinta Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT02015637    
Other Study ID Numbers: ML-3341-304
First Posted: December 19, 2013    Key Record Dates
Results First Posted: April 26, 2018
Last Update Posted: June 20, 2018
Last Verified: May 2018
Keywords provided by Melinta Therapeutics, Inc.:
Gonorrhea
N. gonorrhoeae
bacterial infection
Anti-Infective Agents
Anti-Bacterial Agents
Additional relevant MeSH terms:
Layout table for MeSH terms
Gonorrhea
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Sexually Transmitted Diseases, Bacterial
Sexually Transmitted Diseases
Infection
Ceftriaxone
Delafloxacin
Anti-Bacterial Agents
Anti-Infective Agents